KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Safety and efficacy of tamoxifen in non-ambulant patients with Duchenne muscular dystrophy: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (TAMDMD Group B).

Bettina C Henzi, Niveditha Putananickal, Simone Schmidt, Sara Nagy, Daniela Rubino-Nacht, Sabine Schaedelin, Helge Amthor, Anne-Marie Childs, Nicolas Deconinck, Iain Horrocks, Saskia Houwen-van Opstal, Vincent Laugel, Mercedes Lopez Lobato, Andrés Nascimento Osorio, Ulrike Schara-Schmidt, Stefan Spinty, Arpad von Moers, Fiona Lawrence, Patricia Hafner, Olivier M Dorchies, Dirk Fischer

Neuromuscul Disord 47 105275

PMID39879732
PMCID-
DOI10.1016/j.nmd.2025.105275
发表日期2025-01-29
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Most patients with Duchenne muscular dystrophy (DMD) are non-ambulant. Preserving proximal motor function is crucial, rarely studied. Tamoxifen, a selective oestrogen receptor modulator, reduced signs of muscular pathology in a DMD mouse model. Our objective was to assess the safety and efficacy of tamoxifen over 48 weeks in non-ambulant DMD patients. In this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at six European centres boys aged 10-16 years with genetically diagnosed DMD, non-ambulant and off corticosteroid treatment for ≥6 months, randomly assigned (1:1) to either 20 mg/day tamoxifen orally or placebo were included. The primary outcome was change in D2 motor function measure from baseline to week 48. Of 15 non-ambulant male patients with DMD screened, 14 were enrolled from January 24th, 2019, to January 6th, 2021. Eight patients were randomised to the treatment and six to the placebo group. The primary efficacy outcome did not differ significantly between tamoxifen and placebo (7.8 percentage points, 95 % CI, -26.82 to 11.22, p=0.359) with a trend not favouring tamoxifen. No deaths or life-threatening serious AEs occurred. Tamoxifen was safe but due to insufficient clinical evidence, it cannot be recommended as a treatment option for DMD. Trial registration: ClinicalTrials.gov (NCT03354039).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。